



Blue Vision A/S

Strandgade 24C, st.tv.

1401 Copenhagen K

Annual report 2021

For presentation at the
Annual General Meeting on
25 April 2022

This is an English translation of the Danish version, if there is any inconsistency the Danish version shall prevail

Content

Management endorsement	2
Audit report of the independent auditor	3
Management Report	9
Company information	9
Main activity and strategy	10
Company profit and financial situation	10
Comparison with previous results	11
Capital ratio	11
Outlook for 2022	12
Claims for damages against former management	13
Events after the end of the financial year	13
Main and key figures for the company	14
Corporate governance and corporate governance statement	15
Statement of social responsibility and underrepresented gender	17
Knowledge Resources	17
Data Ethics	17
Shareholder Information	17
Company announcements	22
Annual report 1 January – 31 December 2021	25
Profit and loss account	25
Comprehensive income statement	25
Balance	26
Cash flow statement	28
Statement of equity	29
Notes to the financial statements	30

Management endorsement

Today, the Board of Directors and the Executive Management have considered and approved the annual report for 2021 for Blue Vision A/S.

The annual report is presented in accordance with international financial reporting standards, IFRS, which are approved by the EU and additional requirements in the Financial Statements Act.

We believe that the financial statements give a true and fair view of the company's assets, liabilities and financial position as at 31 December 2021, as well as of the result of the company's activities and cash flows for the financial year 1 January – 31 December 2021.

In our opinion, the management report contains a true and fair account of developments in the company's activities and financial conditions, results for the year, cash flows and financial position, as well as a description of the material risks and uncertainties that the company faces.

The annual report is recommended for approval by the general meeting.

Copenhagen, 31 March 2022

Executive board:

Jeanette Gyldstoft Borg
Director

Board:

Peter Ole Jensen
Chairman

Claus Abildstrøm

Jeanette Gyldstoft Borg

Audit report of the independent auditor

To the shareholders of Blue Vision A/S

Conclusion

We have audited the financial statements of Blue Vision A/S for the financial year 1 January – 31 December 2021, which include income statement, comprehensive income statement, balance sheet, equity statement, cash flow statement and notes, including accounting policies, for the company. The financial statements are prepared in accordance with International Financial Reporting Standards as approved by EU and additional requirements in the Danish Financial Statements Act.

We believe that the financial statements give a true and fair view of the Company's assets, liabilities and financial position as at 31 December 2021 as well as of the result of the Company's activities and cash flows for the financial year 1 January – 31 December 2021 in accordance with international financial reporting standards as approved by the EU and additional requirements in the Danish Financial Statements Act.

Our conclusion is consistent with our audit report to the Board of Directors.

Foundation for conclusion

We have carried out our audit in accordance with international standards on auditing and the additional requirements applicable in Denmark. Our responsibilities according to these standards and requirements are described in more detail in the audit report's report 'Auditor's responsibility for the audit of the financial statements'. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Guidelines on The Ethical Conduct of Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, just as we have fulfilled our other ethical obligations under these requirements and the IESBA Code. We are of the opinion that the audit evidence obtained is sufficient and appropriate as a basis for our conclusion.

To the best of our knowledge, no prohibited non-audit services have been provided within the meaning of Article 5(1) of Regulation (EU) No 537/2014.

We were first elected as auditor for Blue Vision A/S on 8 January 2020 for the financial year 2019, and have been re-elected annually by resolution of the general meeting for a total task period of two years up to and including the financial year 2021.

Key aspects of the audit

Key aspects of the audit are the factors that, in our professional opinion, were most significant in our audit of the financial statements for the financial year 2021. These matters were addressed as part of our audit of the financial statements as a whole and the form of our conclusion thereon. We do not give a separate conclusion on these matters.

Description of key aspects of the audit

Description of key aspects of the audit	How our audit addressed the issue
--	--

<p><i>Assessment of capital and liquidity conditions for 2021</i></p> <p>As of December 31, 2021, the Company has short-term liabilities totalling 14.5 mio.kr, of which 2.7 mio.kr. represents convertible debt that does not represent liquidity draws in 2022, and of which 1.5 million. KR. represents provisions for surety obligations, where also is not aware that they will result liquidity draw in 2022.</p> <p>The company has current assets of 0.1 mio.kr. as of December 31, 2021.</p> <p>The redemption of the short-term debt obligations is thus dependent on the ongoing negotiations with the shareholders of Reponex Pharmaceuticals A/S and, secondarily, on the possibilities of redemption or sale of the company's receivables from Portinho S.A.</p> <p>The Company expects to announce tender offers to the shareholders of Reponex Pharmaceuticals A/S soon, which will strengthen the Company's capital and liquidity ratio in the form of (a) issuance of subscription rights will provide liquidity to the Company, (b) debt reduction in the form of convertible debt being converted into equity and (c) ensure the company a possible future earnings base.</p> <p>As a result of the above conditions, the assessment of the company's capital and liquidity ratio is a key factor in the audit.</p> <p>We refer to notes 1, 8, 10, 11, 12, 14 and 18 of the financial statements.</p>	<p>We have</p> <ul style="list-style-type: none"> • as part of the review of management's assessment of the company's capital and liquidity ratio, the following has been carried out: • We have reviewed and challenged management's operating and cash flow budget for 2022, updated in March 2022. • We have reviewed agreements with the Company's financial creditors in order to verify maturity dates and terms, including terms for loans granted with conversion terms. • We have reviewed draft tender offers to the shareholders of Reponex to assess the potential impact of the acquisition on the Company's capital and liquidity ratio. • Based on available knowledge, we have reviewed and challenged management's assessment of whether surety obligations recognised with a provision of 1.5 mio.kr are not considered to result in liquidity draws in 2022. • We have reviewed and challenged the management's assessment that the Portinho receivable can be realized as early as 2022, if necessary to ensure the company sufficient liquidity in 2022. <p>We has also assessed whether note information is sufficient and sufficient to describe the basis and assumptions for management's assessment of capital and liquidity conditions for 2021.</p>
--	---

<p><i>Valuation of long-term receivables</i></p> <p>In 2018, Blue Vision A/S sold Portinho S.A. for a total of EUR 11 million. In 2021, an agreement has been entered into on payment deferral until 1 July 2023.</p> <p>As of December 31, 2021, the receivable, converted into Danish kroner, has been recognized at an carrying value of 63.5 mio.kr. calculated at a calculated present value based on the debtor being able to meet the receivable as of July 1, 2023, and where discounting is based on an estimated risk assessment.</p> <p>The company has the right to realize the Portinho S.A receivable early by selling the receivable to the 3rd man.</p> <p>The valuation of the receivable is subject to considerable uncertainty and we consider valuation, presentation in balance e and mention in the notes of the receivable as a key aspect of the audit.</p> <p>We refer to notes 1 and 8 of the financial statements.</p>	<p>As part of an audit of management's assessment of the value of the receivable, we have made the following:</p> <ul style="list-style-type: none"> • Discussed and challenged management's assessment that the receivable will be settled at least the carrying value no later than the agreed due date. • We have collected information about ongoing sales and financing efforts for Portinho S.A, which the company's management is aware of and which will enable Portinho S.A. to subsequently repay the receivable to Blue Vision A/S. • We have reviewed the basis for determining the risk-based discount factor used when calculating the net present value of the receivable as of December 31, 2021. <p>We have also assessed whether note information is sufficient and complete to determine the valuation and the related assumptions, assumptions and uncertainties.</p>
--	--

Opinion on the management report

Management is responsible for the management report.

Our conclusion on the financial statements does not include the management report, and we do not express any kind of conclusion with certainty about the management report.

In connection with our audit of the financial statements, it is our responsibility to read the management report and consider whether the management report is materially inconsistent with the financial statements, or our knowledge gained from the audit or otherwise appears to contain material misstatement.

In addition, our responsibility is to consider whether the management report contains the required information in accordance with the Danish Financial Statements Act.

Based on the work carried out, we are of the opinion that the management report is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We have not found any material misstatement in the management report.

Management's responsibility for the financial statements

Management is responsible for the preparation of annual accounts that give a true and fair view in accordance with international financial reporting standards as approved by the EU and additional requirements in the Danish Financial Statements Act. Management is also responsible for the internal control that management deems necessary to prepare financial statements without material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue operations, disclosing matters relating to continued operations where applicable, and preparing the financial statements on the basis of the accounting principle of continued operations, unless management either intends to liquidate the company, discontinues the business or has no realistic alternative but to do so.

Auditor's responsibility for auditing the financial statements

Our aim is to obtain a high degree of assurance as to whether the financial statements as a whole are free of material misstatement, whether due fraud or error, and to issue an audit report with a conclusion. High levels of assurance are a high level of security, but are not a guarantee that an audit carried out in accordance with international standards on auditing and the additional requirements applicable in Denmark will always uncover material misstatement when it exists. Misstatements may arise from fraud or error and may be considered material if it can reasonably be expected that it will influence, individually or collectively, the financial decisions taken by accounting users on the basis of the financial statements.

As part of an audit carried out in accordance with international standards on auditing and the additional requirements that apply in Denmark, we make professional assessments and maintain professional scepticism during the audit. In addition,

- identify and assess the risk of material misstatement in the financial statements, whether due to fraud or error, perform audit procedures in response to these risks, and obtain audit evidence that is sufficient and appropriate to inform our conclusion. The risk of failure to detect material misstatement caused by fraud is higher than that of material misstatement caused by errors, as fraud may include conspiracy, forgery, deliberate omissions, misrepresentation or breach of internal control
- we gain an understanding of internal control relevant to auditing in order to design audit procedures appropriate to the circumstances, but not to express a conclusion on the effectiveness of the company's internal control;

- we will consider whether the accounting policies used by the management are appropriate and whether the accounting estimates and related information prepared by management are reasonable;
- we conclude whether management's preparation of the financial statements on the basis of the accounting principle of continued operations is appropriate and whether, on the basis of the audit evidence obtained, there is material uncertainty associated with events or circumstances that could create significant doubts about the company's ability to continue operations. If we conclude that there is material uncertainty, we must disclose in our audit report information in the financial statements or, if such information is not sufficient, modify our conclusion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or circumstances may result in the Company no longer being able to continue operations.
- we consider the overall presentation, structure and content of the financial statements, including the note information, and whether the financial statements reflect the underlying transactions and events in such a way that a true and fair view is given.

We communicate with senior management about, among other things, the planned scope and timing of the audit, as well as significant audit observations, including any significant internal control deficiencies that we identify during the audit.

We also provide a statement to senior management that we have complied with relevant ethical requirements regarding independence and disclose to it all relationships and other matters that are reasonably likely to affect our independence and, where appropriate, related safeguards.

Based on the conditions communicated to senior management, we determine which factors were most significant in the audit of the financial statements for the current period, and thus are key factors in the audit. We describe these matters in our audit report, unless law or other regulation precludes the disclosure of the relationship, or in the extremely rare cases where we determine that the matter should not be communicated in our audit report because the adverse consequences here could reasonably be expected to outweigh the public interest benefits from such communications.

Declaration of compliance with the ESEF Regulation

As part of the audit of the financial statements of Blue Vision A/S, we have carried out surveys in order to express a conclusion as to whether the annual report for the financial year 1 January to 31 December 2021, with the file name BLUEVISION-2021-12-31.xHTML, has been prepared in accordance with the European Commission Delegated Regulation 2019/815 on the Common Electronic Reporting Format (ESEF Regulation), which contains requirements for the preparation of an annual report in XHTML format.

Management is responsible for preparing an annual report that complies with the ESEF Regulation, including the preparation of an annual report in XHTML format.

Our responsibility is, based on the evidence obtained, to obtain a high degree of certainty as to whether the annual report has been prepared in accordance with the ESF Regulation in all

material respects and to express a conclusion. The action includes checking whether the annual report has been prepared in XHTML format.

We believe that the annual report for the financial year 1 January - 31 December 2021, with the file name BLUEVISION-2021-12-31.xHTML, has been prepared in all material respects in accordance with the ESEF Regulation.

Copenhagen, 31 March 2022

Deloitte Statsautoriseret Revisionspartnerselskab
CVR no. 33963556

Kim Tataka Mücke
Chartered Accountant mne10944

Management report

Company information

Blue Vision A/S Strandgade
24C, st.tv.
1401 Copenhagen K
Telephone: +45 3118 7057
Homepage: www.blue-vision.dk
Email: j.borg@bluevision.dk
CVR no.: 26 79 14 13
Founded: 20 September 2002
Fiscal year: 1 January - 31 December
Municipality of origin: Copenhagen

Board

Peter Ole Jensen (chairman)
Claus Abildstrøm
Jeanette Gyldstoff Borg

Executive board

Jeanette Gyldstoff Borg

Audit

Deloitte Statsautoriseret Revisionspartnerselskab Weidekampsgade
6
2300 Copenhagen

General assembly

The Annual General Meeting will be held on 25 April 2022 at 10.00.

Management report

Main activity and strategy

Blue Vision A/S is a Danish listed company.

Blue Vision A/S' only asset is currently to own a receivable with principal amount of DKK 71.3 million due on 1 July 2023.

On 10 November 2021, the extraordinary general meeting of the company decided to amend the company's mission statement to:

"The company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to invest in shares admitted to trading on a regulated marketplace or multilateral trading facility and not listed shares according to the board's specification in order to achieve long-term value added in accordance with appropriate risk diversification and other related activities".

The amendment should be seen in connection with the fact that at the same extraordinary general meeting the Company's management was authorised to make an offer to buy all or part of the shares in Reponex Pharmaceuticals A/S ("Reponex") cvr.nr. 30 08 23 46, Slotsmarken 12, 1.th., DK2970 Hørsholm, for a fee to the selling Reponex shareholders, which is corrected by the issuance of new shares in the Company.

Work is underway to finalize the tender offer to Reponex as disclosed in company announcement no. 5/2022.

As the Company's mission statement does not correspond to the Company's current identity, Nasdaq Copenhagen granted the Company observation status on 19 October 2021.

The company's profit and financial situation

The result for the year was 5.4 mio.kr. (2020: -32.9 million).

The result has been positively impacted by an upward adjustment of 4.8 mio.kr. of long-term receivables from the sale of Portinho S.A with principal amount of 71.3 mio.kr. excluding accrued interest. The value of the receivable includes a material accounting estimate until the receivable is fully settled with a contractual maturity date of July 1, 2023. The financial statements for 2020 included a write-down/discount effect of 13.8 mio.kr. Due to maturity shortening, 4.8 mio.kr of the impairment/discount effect has been reversed in 2021, which affects the company's result correspondingly positively.

Similarly, the result is positively affected by interest income of approx. DKK 1.2 million arising from the receivable. Interest is due and payable on 1 July 2023.

In the annual accounts for 2020, Blue Vision A/S made provisions totalling DKK 10 million to cover guarantee obligations. The provisions were based on a conservative risk-based estimate. In October 2021, the company entered into an agreement on a joint and several guarantee of approx. DKK 9.2 million for a total payment of 7.0 mio.kr., where 0.5 mio.kr. is paid in 2021 and the rest is paid on 1 July 2023 or if payments are received regarding Portinho'sr receivables before then. The company continues to have provisions for other potential guarantee obligations of 1.5 mio.kr. and in 2021 has thus reversed and revenue-recognised 1.5 mio.kr of the provision for surety obligations.

Management report

In addition to common operating expenses, which are found to be at a satisfactory level, 2021 has been affected by special advisory costs as well as transaction costs related to the proposed acquisition of Reponex (see below).

Equity as at 31 December 2021 amounts to 42.6 mio.kr compared to 34.3 mio.kr as at 31 December 2020.

In addition to the performance-affecting conditions mentioned above, equity in 2021 has been strengthened by converting debt of DKK 2.9 million into share capital.

Comparison with previous performance announcements

Due to the special conditions in the company, the company has not previously announced its profit expectations for 2021.

Capital ratio

As of 31 December 2021, Blue Vision A/S has short-term debt obligations totalling DKK 14.5 million.

of which:

- DKK 8.5 million is bank debt, where after the balance sheet date, an agreement has been entered into on monthly repayments until 1 October 2022, when the outstanding debt becomes due and payable.
- 0.7 mio.kr. are ordinary creditors with ordinary maturity conditions.
- 0.6 mio.kr. is debt to shareholders or related parties to the capital taken out as a standing loan. The debt must be seen in the context of the statement of support given by the company's director Jeanette Borg totalling 0.5 mio.kr. in connection with the presentation of the annual accounts for 2020.
- 0.5 mio.kr. in loans from 3.part, which is due on 1 October 2022.
- 2.7 mio.kr. in convertible debt with conversion rights and conversion obligations in 2022. If conversion rights or conversion obligations are not invoked in 2022, the debt will become due on 14 July 2022.
- 1.5 mio.kr. in the context of potential guarantee obligations. To date, no information has been received that the guarantee obligation is being updated, and thus there are currently no payment obligations in 2022.

As of 31 December 2021, Blue Vision A/S also has long-term debt obligations for a total of 6.6 mio.kr:

- 6.6 mio.kr. in financial loan (including interest accrued at 0.1 mio.kr.) arising from the surety settlement agreement, for which 8.5 mio.kr was set aside. in 2020, and where in 2021 an agreement has been reached on the payment of 7 mio.kr. where

Management report

0.5 mio.kr. is paid in 2021 and the remaining DKK 6.5 million is due upon payment of the Portinho receivable, but no later than 20 November 2023.

In addition, the Company may and must expect extraordinary costs to complete the intended acquisition of Reponex (so-called transaction costs) in addition to funds for ordinary operating expenses in the region of 1.3 mio.kr in the financial year 2022.

It has thus been a bound and priority task for the Company to address the challenges posed by the outlined short-term debt situation – separately the bank debt – against the consideration of the proposed acquisition strategy, under which, in addition to the consideration of own shareholders and of the Company's creditors and partners in general, there have also been considerations - and not e least need for - a comprehensive solution to the immediate and pre-transaction liquidity challenges that Blue Vision A/S anticipated at the end of the financial year 2021.

The efforts to find a balanced solution to the challenges outlined above led to an unforeseen extension of the tender offer process, as also disclosed in the Company Announcements No. 3 of 18 January 2022 and No. 5 of 8 February 2022.

Through the intervention of:

- a binding funding commitment from the 3rd man of up to 3 mio.kr.,
- maturity extension of bank debt until 1 October 2022 as indicated above;
- At the beginning of January 2022, the company owned by the company's chairman of the board of directors has provided a subordinated convertible loan of 0.9 mio.kr. against cash payment available, whereby certain known as expected ordinary operating creditors could be paid until the end of Q1 2022.
- that lenders representing debt for total 1.1 mio.kr. in a joint dedication to implementing the acquisition strategy of Reponex, acceptance has an earliest to request the redemption of these balances as of October 1, 2022.

The proposed acquisition of Reponex is subject to a number of conditions, including, as previously described, most recently in the Company's announcement no. 21 of 19 October 2021:

- that the shareholders of Reponex Pharmaceuticals A/S approve the sale and that at least 67% of the Reponex shareholders, including all shareholders who each directly or indirectly own more than 10% of the share capital in Reponex, agree to sell their shares to Blue Vision A/S for consideration in the form of newly issued A shares in Blue Vision A/S.
- that mutually satisfactory due diligence is carried out.
- that approval is obtained from relevant authorities, etc., including the Danish Financial Supervisory Authority and Nasdaq OMX Copenhagen of the prospectus for the issuance and admission to trading of the new shares in the Company.

Management report

If the acquisition of Reponex is completed by issuing new A shares in Blue Vision A/S to the selling Reponex shareholders, subordinated convertible loans (2.7 mio.kr pr. 31.12.2021 and 0.9 mio.kr. issued after the balance sheet date) will be converted into share capital.

In connection with the initiatives implemented, management assesses that certainty has been achieved for continued operations in 2022, and the annual accounts are presented both with continued operations in mind and with an expectation that the acquisition of Reponex will be completed.

Outlook for 2022

Due to the company's special circumstances, no performance targets for 2022 are currently announced. Performance targets will be announced when the Reponex transaction is completed.

Claims for damages against former management

On 5 March 2021, Blue Vision A/S filed a claim for damages against the sellers of Heartcare ApS and separately Blue Vision A/S' former chairman Nicolai Dines Kærgaard and former CEO Peter Hauge Jensen. The provisional claim for damages amounts to 15.0 mio.kr. Likewise, it is claimed that the sellers of Heartcare ApS return the purchase price of a total of nominally 4 mio.kr shares. The requirements are not included in the company's balance sheet. Blue Vision A/S currently uncovers the possibility of divesting the claim itself to another independent legal entity that is not affiliated or affiliated to Blue Vision A/S, where another legal entity will conduct the case against obtaining a share of the compensation proceeds.

The claims for damages are not included in Blue Vision A/S' balance sheet, and therefore only information in this regard will be available to the market in cases that accrue net proceeds.

Events after the end of the financial year

After the balance sheet date, the company has entered into agreements with lending banks to extend the maturity date for operating certificates for a total of 8.5 mio.kr., after which the debt will be settled with monthly repayments until 1 October 2022, when the remaining debt thereafter becomes due for full and final repayment.

After the balance sheet date, the Company entered into agreements with financial lenders for the provision of additional subordinated convertible loans for 0.9 mio.kr and a loan facility of 3 mio.kr from a 3.part. The subordinated convertible loan is granted on the same terms as the subordinated convertible loans included in the balance sheet per month. December 31, 2021, so that there will be no maturity of liquid amounts in 2022. The 3 mio.kr loan facility. payable on an ongoing basis in 2022 and due on 1 October 2022.

In March 2022, the Company's CEO Jeanette G. Borg resigned from the position of resignation on 29 April 2022.

Management report

1
13

Main and key figures for the company

tkr.	2021	2020	2019	2018	2017 3)
Income statement					
Operating profit	-1,444	-2,135	-1,671	-1,673	-1,983
Loss/Gain Portfolio Investments/Portinho S.A	6,349	-30,468	-12,716	-9,528	0
Profit or loss on financial items	-665	-272	-30	3,488	2,160
Profit for the year	5,392	-32,875	-14,417	-7,713	177
Balance sheet					
Non-current assets	63,500	57,500	0	1,723	0
Assets for sale	0	0	0	78 987	74.631
Total assets	63,645	57,581	72,397	80,838	86,300
Share capital 2)	18,655	83,192	83,192	119,092	119,092
Equity	42,566	34,281	67,155	77,572	85,091
Current liabilities	14,497	23,301	5,242	3,266	1,209
Cash flows					
Cash flow from operations	-2,089	-9,905	-274	-1,579	-4,921
Cash flow from investment net	0	0	1,650	0	0
Cash flow from financing	2,089	9,904	-1,376	1,577	5,423
Total cash flow	0	-1	0	-2	502
Key figures 1)					
Solvency ratio	66.88%	59.6%	92.8%	96.0%	98.6%
Earnings per share (EPS Basic), DKK 1)	0.19	-1.94	-0.14	-0.06	0.00
Diluted earnings per share (EPS-D), DKK 1)	0.19	-1.94	-0.14	-0.06	0.00
Per share a nom. 1 kr. (stated in kr.)					
Nominal value per share	1 1		1 1	1	1
Net asset value per share capital	2.28	0.41	0.81	0.65	0.71
Stock exchange rate (last trade) 2)	1.12	1.89	3.66	0.50	0.31

1) Profit and diluted earnings per share have been calculated in accordance with IAS 33. Other key figures have been prepared in accordance with the latest version of the Danish Financial Analysts' Association's "Recommendations and Key Figures". See note 19.

2) The stock exchange price as of 31 December 2021 is based on 14,542,437 A shares.

3) The company changed the presentation form of the income statement and balance sheet in 2019. Comparative figures for 2017 are not adapted.

Management report

Corporate governance and corporate governance statement

Blue Vision A/S' Board of Directors and Executive Management continuously seek to ensure that the company's management structure and control systems are appropriate and function satisfactorily. A number of internal policies and procedures have been developed and maintained on an ongoing basis with a view to ensuring active, safe and profitable management of the company.

Blue Vision A/S has prepared a statutory report on corporate governance, cf. section 107b of the Danish Financial Statements Act, for the financial year 2021 and publishes it on the company's website <http://www.blue-vision.dk/index.php/da/om-blue-vision/virksomhedsledelse> at the same time as the publication of the annual report for 2021.

The statutory report is divided into three sections:

- An account of Blue Vision A/S' work with the Recommendations on Corporate Governance. On 2 December 2020, the Committee on Corporate Governance published updated Recommendations on Corporate Governance, effective from 1 January 2021, based on the "comply or comply" principle. It is the opinion of the Board of Directors that the Recommendations for Corporate Governance are essentially followed by Blue Vision A/S' management, taking into account the size and special nature of the company.
- A description of the main elements of Blue Vision A/S' internal control and risk management system in connection with financial reporting.
- A description of the composition of Blue Vision A/S' management bodies, their committees and their function.

In addition to the above description, the company's home office explains, in accordance with the Recommendations, how the company meets the individual points of the recommendations.

Board members and other management duties

Chairman of the Board Mr. Peter Ole Jensen – joined the Board of Directors on 31 December 2020

- Pole Holding ApS, Ceo
- SG24D ApS, director Peter Ole Jensen is 60 years old.

In particular, Peter Ole Jensen's experience in management as well as negotiation technique and strategy are found to be of value and relevance to Blue Vision A/S.

Peter Ole Jensen is a major shareholder at Blue Vision A/S.

Board member Attorney Mr. Claus Abildstrøm – joined the Board of Directors on 30 April 2014:

- Fanum A/S, board member
- Kolind A/S, board member
- CAAB Consulting ApS, Director
- PII A/S, board member
- Danders & More Advokatpartnerselskab, Chairman of the Board
- DM Komplementar Advokatpartnerselskab, board member
- Kolind Invest A/S, Board member
- AB A/S, member of the Board of Directors
- Nordholm ApS, board member

Management report

- SPC Holdings A/S, Board member

Claus Abildstrøm is 58 years old.

In particular, Claus Abildstrøm's board and legal competencies are of great value and relevance to Blue Vision A/S.

Claus Abildstrøm is a partner in Danders & More, which to a limited extent has exercised legal advice and work for Blue Vision A/S during the accounting period.

Board member Fr. Jeanette Gyldstoft. Castle:

- Haab Investments Ltd, Director
- Portinho ApS, Director
- Baltic Investment Group ApS, Ceo
- Claritas Consulting GmbH, director Jeanette Gyldstoft Borg is 56 years old.

In particular, Jeanette Gyldstoft Borg's administrative and versatile and long-standing managerial skills are relevant to Blue Vision A/S.

Jeanette Gyldstoft Borg has special interests in Portinho S.A., where Blue Vision has a significant receivable, which as of 31 December 2021 is included in the annual accounts with a value of 63.5 mio.kr. Jeanette Gyldstoft Borg is also a major shareholder in Blue Vision A/S.

Jeanette Gyldstoft Borg is also CEO of Blue Vision A/S.

Other information

The Board of Directors is composed with a view to obtaining special competencies in order to handle Blue Vision A/S' current and present affairs as well as the implementation of Blue Vision A/S' strategy.

In addition, it is considered essential that the board has general management experience, particularly in the management of listed companies and economic and financial know-how.

Members of the Board of Directors are generally elected at the Annual General Meeting for one year at a time. The Management Board shall elect a Chairman from among its members. A Deputy Chairman of the Management Board shall not be appointed.

Due to the company's special circumstances, the entire Board of Directors also constitutes the company's audit committee.

Management remuneration, Remuneration reporting, Incentive programmes

The Company's Executive Management and Board of Directors have not received remuneration in 2020 and 2021. In 2021, costs have been incurred for a law firm in which a board member is a partner, with 105 t.kr.

(2020: 935 t.kr.)

The company has no incentive programs.

The Company will submit a remuneration report, which will be published at the same time as the notice convening the Annual General Meeting, where the Company will also publish proposals for a future remuneration policy for remuneration of the Executive Management and the Board of Directors.

Management report

Statement of social responsibility and underrepresented gender

Cf. section 99a of the Danish Financial Statements Act, Blue Vision A/S must make an account of policies, actions and results regarding social responsibility and includes the following four points:

- Human rights
- Environmental impact
- Reducing climate impacts
- Anti-corruption and bribery

Due to the company's size and limited level of activity, including the number of employees, the Company does not currently consider it necessary to prepare actual policies and guidelines for the above.

The Company assesses on an ongoing basis and in line with the Company's development and future plans whether actual guidelines for social responsibility and points below should be prepared.

The company has chosen to have a target figure of 20% insofar as the board members elected by the general meeting must be made up of the underrepresented gender. The goal is currently met, as the company has 3 board members, one of whom is a woman.

Due to the fact that the company does not currently have any employees other than the company's CEO, no goals and policies have been set for the Executive Management, however, it is noted that Blue Vision A/S' CEO is a woman.

The Company's goals and policies for the unrepresented gender will be adjusted on an ongoing basis in line with the Company's development and activity.

Knowledge resources

As the company's board and management, Blue Vision A/S collectively represents a broad experience and know-how in business operations, turn-arounds, investment in companies, real estate and general financing of the purchase and sale of companies and real estate as well as strategy development and its implementation.

In addition, the company's Board of Directors also possesses experience in the management of listed companies.

Data ethics

Taking into account Blue Vision A/S' current situation and limited level of activity, the Company has not yet considered it necessary to prepare a data ethics policy, and consequently the Company does not prepare a statement on the Company's work with and policy on data ethics issues.

Within the limited areas where the Company's current limited activities involve contact with data ethics issues, the Company strives in its operations to comply with data ethical recommendations.

Management report

Shareholder information

Equity

The registered share capital as at 31 December 2020 was DKK 83,092,270, divided into 13,042,027 A shares of DKK 1 and 70,050,243 B shares of DKK 1, of which DKK 67,183,043 were the Company's treasury shares.

On 31 December 2020, Blue Vision A/S' annual general meeting decided to reduce the company's share capital by a total of nominally DKK 67,183,043 at a price of DKK 100 for a special reserve.

The capital reduction was finally implemented and registered on 2 March 2021, after which the registered share capital amounted to DKK 15,909,227, divided into 13,042,027 A shares of DKK 1 and 2,867,200 B shares of DKK 1.

On 29 October 2021, the Company converted debt totalling DKK 2,890,000 into 2,745,610 shares divided into 1,500,410 A shares of DKK 1 and 1,245,200 B shares of DKK 1, after which the share capital amounts to 18,654,837 shares of DKK 1 divided into 14,542,437 A shares and 4,112,400 B shares.

Amendments to the Staff Regulations

The company's articles of association may be amended by adopting the resolution with at least 2/3 of both the votes cast and the voting share capital represented at the general meeting.

Amendments were made at Blue Vision A/S extraordinary general meeting on 10 November 2021, including the purpose clause, as described under "Main activity and strategy".

Powers

In accordance with Articles of Association 4.1.A – C of the Company, the Board of Directors is authorised, in the period up to 31 August 2024, to:

Cf. section 4.1.A. to increase the company's share capital by up to nominally DKK 50,000,000 on one or more occasions. The increase may be made by full cash payment, by conversion of debt or as a deposit in non-cash values, including deposits by an existing company. The capital increase shall include pre-emptive rights for existing shareholders. The new shares must be transfer instruments and be registered in the company's register of shareholders, cf. article 3.2 of the Articles of Association. The new shares' right to dividends and other rights in the company shall commence from the date decided by the Board of Directors, but no later than the first financial year following the year of registration of the capital increase.

Cf. section 4.1.B. to increase the company's share capital by up to a nominal value of DKK 1,100,000,000 A and/or B shares of DKK 1 each. The increase may be made by total or partial cash payment, by conversion of debt and/or payment in non-cash values, including deposits by an existing company. The capital increase must be without pre-emptive rights for existing shareholders, as it is a directed issue. When paying in cash or converting debt, the capital increase must be made at least at the market price calculated as the average for the last 3 stock exchange days before the subscription. In the event of a contribution of other assets in the form of shares in Reponex Pharmaceuticals A/S, CVR No. 30082346, the subscription price must be 157, if this price is confirmed by the final valuation report, so that for each share of nom.

Management report

DKK 1, values of at least DKK 1.57 must be deposited. The new A shares must be negotiable, while the new B shares must be non-negotiable. There shall be no restrictions on the transferability or pre-emptive rights of the new A or B shares in the event of future capital increases, unless otherwise stated in the articles of association or determined by the general meeting. Both A and B shares must be listed on the register of shareholders of the company, cf. article 3.2 of the Articles of Association. The new shares' right to dividends and other rights in the company shall commence from the date fixed by the Board of Directors when subscribing, but not later than the first financial year following the year of registration of the capital increase.

Cf. section 4.1.C. to increase the company's share capital by up to nominally DKK 50,000,000 upon issuance of new B shares. The increase may be made by full cash payment, by conversion of debt or as payment in non-cash values, including deposits by an existing undertaking. The capital increase shall be without pre-emptive rights for existing shareholders and shall be at least at market price. The new B shares are issued in a new independent share class, which the Board of Directors is authorized to establish in connection with the capital increase. The B shares must be non-negotiable and recorded in the company's register of shareholders. The B shares shall not be issued in dematerialised form through VP SECURITIES A/S and shall not be purchased for trading and official listing on NASDAQ Copenhagen. In addition, the B shares must have the same right to dividends and other rights in the company as the company's other shares. The right of the B shares to dividends and other rights in the company shall commence from such time as the Board of Directors may determine, but not later than the first financial year following the year of registration of the capital increase.

By resolution of 31 October 2019, the Board of Directors has exercised the authorisation in Article 4.1C of the Articles of Association to increase the Company's share capital without pre-emptive rights for the existing shareholders by nominally DKK 1,827,200 B shares. The maximum increase in share capital that can be decided on the basis of the authorisation has now been reduced to DKK 48,172,800.

Cf. section 4.1.D. to increase the company's share capital by up to nominally twice the nominal A share capital and B share capital immediately before the date of the Board of Directors' approval to acquire a new company by contribution in kind against the payment of at least 600,000,000 new shares.

The increase can be made by cash payment at price 100 by payment of DKK 1.00 for subscription of each A or B share of DKK 1.00. The capital increase shall include pre-emptive rights for existing shareholders at the time of the Board of Directors' decision to exercise the authorisation for the capital increase referred to in paragraph 1, so that each A share gives the shareholder the right to subscribe for 2 new A shares and each B share gives the shareholder the right to subscribe for 2 new B shares. The new A shares must be negotiable instruments, while the new B shares must be non-negotiable instruments. Both A and B shares must be registered on the name in the company's register of shareholders, cf. article 3.2 of the Articles of Association. The new shares' right to dividends and other rights in the company shall take effect from the date determined by the Board of Directors when subscribing, but no later than the first financial year following the year of registration of the capital increase. The shareholders' pre-emptive rights shall be valid for 3 months from the beginning of the subscription period, which shall be determined by the Board of Directors as soon as possible after exercise of the authorisation. Shares not subscribed for within the 3-month period are offered for free subscription by all shareholders and third parties of the company for an additional subscription period of 3 months from the end of the first subscription period. There

Management report

shall be no restrictions on the transferability or pre-emptive rights of the new A or B shares in the event of future capital increases, unless otherwise stated in the articles of association or determined by the general meeting.

In accordance with Article 4.2 of the Articles of Association of the Danish Companies, the Board of Directors is authorised until 31 August 2024 to allow the Company to issue warrants on one or more occasions. The warrants must not exceed DKK 50,000. 000 shares of the company. The issue must be without pre-emptive rights for existing shareholders and the issue must be made on market terms, however, the Board of Directors is entitled to issue shares in the Company at a preferential price in respect of nominally DKK 2,172,800 A-shares and DKK 2,827,200 B shares. At the same time, the Board of Directors is authorised to make capital increases in the Company on one or more occasions in connection with subsequent exercise of the above-mentioned warrants. The increase shall be without the right of way of the company's former shareholders. The new shares must be negotiable instruments and be registered in the company's register of shareholders, cf. article 3.2 of the Articles of Association. The subscription price is determined by the Board of Directors in connection with the issuance of the warrants and may not be below the market price at the time of issue, however, the Board of Directors is entitled to issue shares in the Company at a preferential price in respect of nominally DKK 2,172,800 A shares and DKK 2,827,200 B shares. The new shares must be paid up in full. The right of shares to dividends and other rights in the company shall commence from the date decided by the Board of Directors, but not later than the first financial year following the year of registration of the capital increase.

According to Article 4.3.A. of the Company's Articles of Association, the Board of Trustees is until 31 August 2026 authorised to allow the Company to borrow on one or more occasions against bonds or other debentures with a right for the lender to convert its claim into A or B shares in the Company (convertible loans). The convertible loans must give the right to subscribe nominally dkk 50,000,000 shares in the company. The subscription of the convertible loans shall be made without pre-emptive rights for the Company's previous shareholders and the admission shall be on market terms, however, the Board of Directors shall be entitled to issue shares in the Company at a preferential price in respect of nominally DKK 2,172,800 A shares and DKK 2,827,200 B shares. At the same time, the Board of Directors is authorized to affect a capital increase in the company on one or more occasions in connection with a later conversion of the above loans. The increase must be made without pre-emptive rights for the company's previous shareholders. The new A shares must be negotiable instruments, while the new B shares must be non-negotiable. The shares must be registered in the company's register of shareholders, cf. article 3.2 of the Articles of Association. The subscription price is fixed by the Board of Directors in connection with the issuance of the convertible loans and must never be below the market price at the time of issue, however, the Board of Directors is entitled to issue shares in the Company at a preferential price in respect of nominally DKK 2,172,800 A shares and DKK 2,827,200 B shares. The new shares must be paid up in full. The rights of the new shares to dividends and other rights in the company shall arise from the date decided by the Board of Directors, but not later than the first financial year following the year of registration of the capital increase.

By resolution of 26 April 2021, the Board of Directors has exercised the previously granted authorisation in article 4.3.A of the Articles of Association without pre-emptive rights for the existing shareholders and at a preferential price, so that there is an unused conversion right for nominally DKK 1,082,000 A shares and nominally DKK 1,582,000 B shares. The conversion right is valid until 26 April 2022. The provisions of § 4.3.A. 4. – 9 paragraphs shall apply

Management report

mutatis mutandis to such conversion. Any conversion does not affect the authority currently available in Article 4.3.A. of the Articles of Association above.

In accordance with Article 4.3.B of the Company's Articles of Association, the Board of Directors is authorised until 23 August 2024 to allow the Company to borrow on one or more occasions against bonds or other debentures with a right for the lender to convert its claim into shares in the Company (convertible loans). The convertible loans may not give the right to subscribe nominally for DKK 6,000,000 shares in the company. Issued but not utilized convertible loans that are no longer convertible may be reissued by the Board of Directors. The subscription of the convertible loan shall be made without pre-emptive rights for the Company's former shareholders and the admission shall be on market terms, however, the Board of Directors shall be entitled to issue shares in the Company at a preferential price in respect of nominally DKK 2,172,800 A shares and DKK 2,827,200 B shares. At the same time, the Board of Directors is authorized to affect a capital increase in the company on one or more occasions in connection with a later conversion of the above loans. The increase shall be made without pre-emptive rights for the company's former shareholders. The new shares must be negotiable instruments and be registered in the company's register of shareholders, cf. article 3.2 of the Articles of Association. The subscription price shall be freely fixed by the Board of Directors in connection with the issue of the convertible loans, except that subscription shall never be made below the price of 100. The new shares must be paid up in full. The rights of the new shares to dividends and other rights in the company shall commence from the date decided by the Board of Directors, but not later than the first financial year following the year of registration of the capital increase.

By resolution of 26 April 2021, the Board of Directors has exercised the authorisation in Article 4.3.B of the Articles of Association without pre-emptive rights for the existing shareholders, and at a preferential price, with respect to a conversion right with nominally DKK 324,306 A-shares and nominally DKK 140,307 B shares. The conversion right is valid until 26 April 2022. The maximum increase in share capital that can be decided on the basis of the authorisation has now been reduced to DKK 49,535,387, of which nominally 4,535.387 can be made at a preferential price.

By decision of 29 October 2021, at the request of the creditor pursuant to the convertible debenture of 26 April 2021 issued in accordance with Article 4.3.B of the Articles of Association, the Board of Directors has increased the Company's share capital without subscription rights for the existing shareholders by nominally DKK 184,000 A shares.

Pursuant to Article 4.4 of the Articles of Association of the Company. The Board of Directors is authorised to lay down the detailed conditions for the capital increases in accordance with the above authorisations and to make such changes to the Company's Articles of Association, including the creation of new classes of capital, which may be necessary as a result of the Board of Directors' exercise of the said authorisations. Any use of the authorisations referred to in clauses 4.1 to 4.3 requires the unanimous agreement of the members of the Board of Directors.

Dividend

Blue Vision A/S has not yet established any actual dividend policy.

The Board of Directors recommends to the Annual General Meeting that no dividend be paid for 2021.

Management report

Own share policy

Pursuant to the authorisation of the general meeting, the company will acquire treasury shares corresponding to up to 10% of the share capital. The Company holds 6,530 treasury A shares as of 31 December 2021. There has been no purchase or sale of treasury shares in 2021. Reference is made to the above mention of the capital reduction of shares that were technically considered own shares in 2021.

Annual General Meeting

The Annual General Meeting will be held on 25 April 2022, at 10:00 a.m.

Financial calendar 2022

The financial calendar for 2022 as last updated is as follows:

31 March 2022	Publication of annual report for 2021
25 April 2022	Holding of the Annual General Meeting for 2021
31 August 2022	Publication of interim report H1 2022
31 March 2023	Publication of annual report for 2022
28 April 2023	Holding of the Annual General Meeting for 2022

Contact Person – Investor Relations

Blue Vision A/S' website www.bluevision.dk further information and all published announcements can be found.

Inquiries regarding relations with investors and the stock market can also be directed to Peter Ole Jensen:

Phone: +45 21220681
 Email: poj@bluevision.dk

Company announcements

Issued company announcements in 2021

In 2021, Blue Vision A/S has issued the following company announcements:

4 January	Changes in the Executive Management Company announcement no. 1
4 January	Status regarding announced claims for damages and receivables Company Announcement No. 2
2 March	Capital reduction completed Company Announcement No. 3
5 March	Clarification of requirements arising from the Heartcare transaction

Management report

	Company Announcement No. 4
8 March	Clarifications and information Company Announcement No. 5
8 March	Correction of financial calendar for 2021 Company announcement No. 6
8 March	Topics for agenda for the Annual General Meeting on 29 April 2021 Company Announcement No. 7
10 March	Information on the receivable Company announcement no. 8
28 March	Correction II of financial calendar for 2021 Company Announcement No. 9
31 March	Annual report 2020 incl. summary Company Announcement No. 10
7 April	Correction of annual report 2020 Company Announcement No. 11
7 April	Notice of annual general meeting Company Announcement No. 12
26. April	Extension of bank debt and raising of convertible loans Company Announcement No. 13
27. April	Updated Annual Report 2020 Company Announcement No. 14
28. April	Major Shareholder Announcement Company Announcement No. 15
29. April	Minutes of the Annual General Meeting Company Announcement No. 16
29. July	Major Shareholder Announcement Company Announcement No. 17
30. August	Interim report for 2021 incl. summary Company Announcement No. 18
13 October	Agreement on settlement of guarantee obligation Company Announcement No. 19
19 October	Implementation of the strategic plan at the investment target Reponex Pharmaceuticals A/S

Management report

	Company Announcement No. 20
19 October	Notice of extraordinary general meeting Company Announcement No. 21
21 October	Information of board candidate Company Announcement No. 22
October 29	Conversion of debt under promissory notes Company Announcement No. 23
7 November	Major shareholder announcement and reporting of senior executive transaction Company Announcement No. 24
November 7	Reporting of senior executive transaction Company Announcement No. 25
10 November	Minutes of extraordinary general meeting Company Announcement No. 26
10 November	Clarification of assessment of Reponex Pharmaceuticals A/S Company Announcement No. 27
15 November	Transfer of claims for damages Company Announcement No. 29
November 17	Correction III of the Financial Calendar for 2021 Company Announcement No. 30
29 December	Financial calendar for 2022 Company Announcement No. 31

Issued company announcements in 2022

In 2022, Blue Vision A/S has issued the following company announcements:

6 January	Convertible borrowing Company announcement No. 1
18 January	Correction – financial calendar 2022 Company Announcement No. 2
18 January	Change of financial calendar and information about tender offer process Company Announcement No. 3
8 February	Correction II – financial calendar for 2022 Company Announcement No. 4
8 February	Change to financial calendar and information on tender offer process and transfer of bank debt

Management report

Company Announcement No. 5

15 February Bank debt carryover
Company announcement No. 6

8 March Deadline for submission of items to be included on the agenda of the Annual General Meeting
on 25 April 2022
Company Announcement No. 7

22 March Change to financial calendar
Company announcement no. 8

22 March Correction III –financial calendar for 2022
Company Announcement No. 9

30 March Termination
Company Announcement No. 10

Expected company announcements in 2022

Blue Vision A/S expects to issue the following additional company announcements etc. in 2022:

April 2022 Expected announcement of tender offer for Reponex

25 April 2022 Minutes of the Annual General Meeting 2021

31 August 2022 Publishes interim report H1 2022

Annual report 1 January – 31 December 2021**Income statement**

t.kr.	Note	2021	2020
		<u> </u>	<u> </u>
Administrative costs	2	-1.444	-2.135
Operating profit		<u>-1.444</u>	<u>-2.135</u>
Value adjustment, etc. regarding receivables from the sale of Portinho S.A.	3	4.849	-13.844
Loss regarding Heartcare ApS	4	1.500	-16.624
Financial income	5	1.151	0
Financial costs	6	-665	-272
Profit before tax		<u>5.391</u>	<u>-32.875</u>
Tax on profit for the year	7	0	0
Earnings per share (EPS basic), DKK	9	0,19	-2,07
Diluted earnings per share (EPS-D), DKK	9	0,19	-2,07

Comprehensive income statement

Profit for the year	5.391	-32.875
Other comprehensive income before and after tax	0	0
Profit for the year	<u>5.391</u>	<u>-32.875</u>

Annual accounts 1 January – 31 December

		5,391	-32,875
Balance sheet			
t.kr.	Note	2021	2020
ASSETS			
Non-current assets			
Receivables from the sale of Portinho S.A	8	63.500	57.500
Total non-current assets		63,500	57,500
		145	82
		63.645	57.582
Current assets			
Receivables		137	82
Period delimitation		8	0
Cash and cash equivalents		0	
Total current assets	Total assets		

Annual accounts 1 January – 31 December

Balance sheet

	Note	2021	2020	
LIABILITIES				
			Equity	
Share capital			18,655	83,092
Carryover result			23,911	-48,811
Total equity	9		42,566	34,281
Long-term liabilities				
Financial loans		10	6,582	0
Total long-term liabilities			6,582	0
Short-term liabilities				
Provisions		11	1,500	10,000
Bank debt		12	8,533	8,479
Debt to shareholders		13	622	1,562
Supplier debt			654	3,260
Subordinated convertible debt		14	2,685	0
Financial loans		10	503	0
Total short-term liabilities		14,497	23,301	Total liabilities
21,079		23,301	63,645	57,582
Total liabilities				

t.kr.	Note	2021	2020
		<i>Blue Vision A/S</i>	
		Annual report 2021	
		CVR no. 26 79 14 13	
Profit for the year		5.392	-32.875
Losses and provisions relating to Heartcare ApS		-1.500	10.000
Annual accounts 1 January – 31 December			
Value adjustment, etc. long-term receivables		-4.849	13.844
Financial items		-485	272
Change in working capital		-30	-901
Cash flows related to primary operating activities		-1.472	-9.660
Interest paid		-617	-245
Cash flow calculations			
Cash flows from operating activities			-2.089
		-9.905	
Capital reduction deposit		0	1.047
Assumption of financial debt		2.589	8.129
Repayment of financial debt		-500	728
Cash flows from investment activity			
		0	0
Cash flow of the year		0	-1
Cash and cash equivalents 1 January		0	1
Cash flow from financing activities		2,089	9,905
Cash and cash equivalents 31 December			
	0 0		
Debt obligations arising from financing activities			
t.kr.		2021	2020

Annual accounts 1 January – 31 December

Debt obligations from financing activity 1 January	10.041	1.157
Debt repayments	-500	0
Carried over from provisions	7.000	0
Transferred from supplier debt	2.685	0
Conversion of debt into equity	-2.893	0
Borrowing	<u>2.589</u>	<u>8.884</u>
Debts from financing activity 31 December	<u><u>18,922</u></u>	<u><u>10,041</u></u>

Financial loans	7,082	0
Bank debt	8,533	8,479
Debt to shareholders	622	1,562
Subordinated convertible debt	<u>2,685</u>	<u>0</u>
Debts from financing activity 31 December	<u><u>18,922</u></u>	<u><u>10,041</u></u>

Statement of own funds

tkr.	Share-Transferred total capital	result	Equity	;
	_____	_____	_____	
Equity 1 January 2020	83.092	-15.936	67.156	
	_____	_____	_____	
Equity movements in 2020				
Profit for the year	0		<u>-32.875</u>	<u>-32.875</u>
			<u>-32.875</u>	<u>-32.875</u>
Equity 31 December 2020	83.092	-48.811	34.281	
	_____	_____	_____	
Equity movements in 2021				
Total income in 2020 total	0			

Annual accounts 1 January – 31 December

Profit for the year		0	
Transactions with owners			
Capital reduction for the purpose of transfer to reserves;	-67.183	67.183	0
Capital increase when converting debt	<u>2.746</u>	<u>147</u>	<u>2.893</u>
Transactions with shareholders	<u>-64.437</u>	<u>67.330</u>	<u>2.893</u>
Equity December 31, 2021	<u>18.655</u>	<u>23.911</u>	<u>42.566</u>
		<u>5.392</u>	<u>5.392</u>
Total income in 2021 total	0	<u>5.392</u>	<u>5.392</u>

Annual accounts 1 January – 31 December

Notes to the financial statements

Note

- 1 Accounting estimates and assessments
- 2 Administrative costs
- 3 Value adjustment, etc. in respect of long-term receivables
- 4 Loss regarding Heartcore ApS
- 5 Financial income
- 6 Financial costs
- 7 Tax
- 8 Long-term receivables
- 9 Equity
- 10 Financial loans

Note

- 11 Provisions
- 12 Bank debt
- 13 Debt to shareholders
- 14 Subordinated convertible debt
- 15 Financial risks and financial instruments
- 16 Related parties
- 17 Contingent assets, liabilities and guarantees
- 18 Events after the balance sheet day
- 19 Accounting policies

Annual accounts 1 January – 31 December Notes

1 Introduction, Accounting Estimates and Assessments

Introduction

Blue Vision A/S is a Danish listed company with registered office: Strandgade 24C st.tv, 1401 Copenhagen K.

The company's purpose is, without geographical limitation, to be a holding company for companies with Life Science activities and to invest in shares raised for trading on a regulated marketplace or multilateral trading facility and unlisted shares according to the board's specification in order to achieve long-term value added while observing appropriate risk diversification and other related activities.

Accounting estimates and assessments

Financing of the company's operations

As of December 31, 2021, the Company has short-term liabilities totalling 14.5 mio.kr. and current assets for 0.1 mio.kr. Of the short-term debt obligations, provisions amount to 1.5 mio.kr to cover potential surety obligations where there is no current debt obligation and therefore, by their very nature, there are no specific payment agreements. Furthermore, subordinated convertible debt of 2.7 mio.kr is included, where lenders have the right to convert the debt into share capital until 31 December 2022, and where there is a conversion obligation if capital increases are implemented, including completion of the acquisition of Reponex Pharmaceuticals A/S by issuing new shares in Blue Vision A/S. If neither conversion right nor conversion obligation becomes applicable in 2022, the subordinated debt will not become due until 14 July 2023.

The company's main asset in the form of receivables from the sale of Portinho S.A has been agreed to become due no later than 1 July 2023. The principal amount (excluding interest accrual) amounts to 71.3 mio.kr, which is recognized at a risk-based present value of 63.5 mio.kr. as of December 31, 2021. Thus, as a rule, the company will not generate liquidity in 2022 to cover the current liabilities. However, the company is continuously exploring the possibilities for the debtor to repay the receivable early or there may be an opportunity to sell the receivable. However, early repayment or sale of the receivable will only take place if proceeds are assessed to be at a satisfactory level.

The company's main short-term maturity obligation in 2022 consists of two bank loans totalling DKK 8.5 million. For both bank loans, repayment plans have been agreed until 1 October 2022, when the remaining debt is due for final settlement. Similarly, it has been agreed that short-term financial loan of 0.5 mio.kr. due on 1 October 2022.

After the balance sheet date, the company has entered into an agreement with a lender for the provision of an additional subordinated convertible loan for 0.9 mio.kr. The subordinated convertible loan has been granted on the same terms as the subordinated convertible loans

Annual accounts 1 January – 31 December

included in the balance sheet as at 31 December 2021, so that there will be no maturity of liquid amounts in 2022.

After the balance sheet date, a loan facility of 3 mio.kr has also been agreed, which will be disbursed on an ongoing basis in 2022 and payable on 1 October 2022.

A number of the debt obligations have agreed to be due on 1 October 2022, which should be seen in connection with the fact that the transaction to acquire Reponex Pharmaceuticals A/S is expected to be finally completed by this time.

From 1 October 2022 at the latest, Blue Vision A/S is expected to be the parent company of a group with Reponex Pharmaceuticals A/S as a subsidiary, and where the majority of the shareholders in the future will, as a starting point, be the current shareholders of Reponex Pharmaceuticals A/S. When the acquisition is completed, Blue Vision A/S will thus be part of the new group's overall liquidity management, and Blue Vision A/S' future liquidity, capital preparedness and solvency must be seen in the context of Reponex Pharmaceutical A/S.

In connection with the implemented initiatives, management assesses that security has been achieved for continued operations in 2022, and the annual accounts for 2021 are presented with continued operations in mind.

Valuation of long-term receivables

The value of long-term receivables includes a material accounting estimate until the receivable is fully settled by July 1, 2023. The principal amount is 71,344 t.kr. In the financial statements for 2020, an impairment of the receivable was recognized by t.kr 13,844, based on the difference between the principal amount of the receivable and the present value of payment as of July 1, 2023, where the discount rate reflected the assessed credit and project risk. The risk is assessed unchanged as of 31 December 2021, but as a result of the maturity shortening against 1 July 2023, 4,849 t.kr of the impairment and income accrual of interest by 1,151 t.kr have been reversed in 2021. The receivable is thus included with an carrying value of t.kr 63,500. as of December 31, 2021.

Please refer to note 8 for further mention, which states that it is still management's assessment that it is considered realistic that the Company will receive full payment of principal plus interest no later than 1 July 2023.

Provisions for guarantee obligations

In the financial statements for 2020, provisions for surety obligations assumed in connection with the previous acquisition of Heartcare ApS and subsidiaries as well as guarantee obligations relating to bank debt in the former subsidiary were included; Contra A/S in bankruptcy for a total of 10 mio.kr. Counterclaims against Contra A/S during bankruptcy are considered lost and were costed as financial loss in 2020 with 4,992 t.kr. (see note 4).

Annual accounts 1 January – 31 December

In 2021, Blue Vision A/S entered into an agreement on the settlement of a guarantee obligation for 7 mio.kr, whereas in 2020, 8.5 mio.kr was set aside. Of this, 0.5 mio.kr has been paid. in 2021 and 6.5 mio.kr. is included as a long-term financial loan as of 31 December 2021 (see note 10). The agreement resulted in the return of 1.5 mio.kr. of the 2020 s provision on income through the income statement. See note 4.

Provisions of 1.5 mio.kr are then set aside. to cover a remaining potential guarantee obligation. According to the information available to Blue Vision A/S, the debtor meets the payment agreement for the underlying loan relationship, and thus no claims have currently been made against Blue Vision A/S. The provision represents the assessed maximum risk on the guarantee obligation assumed by Blue Vision A/S in relation to the strange loan relationship.

Claims brought against former owners of Heartcare ApS and others

As published in the company announcements no. 2/2021, 4/2021 and 29/2021, Blue Vision A/S has concretized claims for damages against the sellers of Heartcare ApS as well as separately Blue Vision A/S' former chairman Nicolai Dines Kærgaard and former CEO Peter Hauge Jensen. The provisional claim for damages amounts to 15.0 mio.kr. Likewise, it is claimed that the sellers of Heartcare ApS return the purchase price of a total of nominal 4 mio.kr shares. The requirements are not included in the company's balance sheet. Blue Vision A/S is currently exploring the possibility of divesting the claims to another independent legal entity that is not affiliated or affiliated to Blue Vision A/S, where the buyer will bear the costs of conducting the cases and with a scheme where net proceeds are shared between Blue Vision A/S and the buyer. No agreements have been concluded for the assignment of claims for the date of submission of these financial statements.

Annual accounts 1 January – 31 December

2 Administrative expenses

t.kr	. 2021	2020
Remuneration for auditor elected by the general meeting		
Statutory audit	-105	-125
Other declaration tasks	-30	0
Tax advice	-	0
Other services	-30	-19
	<u>-165</u>	<u>-144</u>

Other services in both 2021 and 2020 include various accounting sparring with management.

Remuneration to the Board of Directors and executive management

The Board of Directors and the Executive Management have not received remuneration in 2021 (2020: 0 t.kr.).

3 Value adjustment, etc. of long-term receivables

t.kr	. 2021	2020
Value adjustment (Note 8)	4.849	
13.844	<u>4.849</u>	<u>-13.844</u>

4 Loss regarding Heartcare ApS

t.kr	. 2021	2020
Loss on assumption of bank debt from portfolio company loans/interim transactions with portfolio companies	0	-4,992
Provision for guarantee obligation (Notes 1 and 11) (2021: -1,632)	-1,632	Loss on

Annual accounts 1 January – 31 December

	reversal of provision)	<u>1.500</u>	<u>-10.000</u>
		<u>1.500</u>	<u>-16.624</u>
5	Financial income		
	t.kr	. 2021	2020
		_____	_____
	Interest income on long-term receivables	<u>1.151</u>	_____
	0	<u>1.151</u>	<u>_____</u>
	0		
6	Financial costs		
	t.kr	. 2021	2020
		_____	_____
	Interest bank debt, etc.	-408	-245
	Interest debt to capital owners	-9	-27
	Other interest	-248	0
		<u>-665</u>	<u>-272</u>
7	Tax		
	t.kr	. 2021	2020
		_____	_____
	Tax on the profit for the year can be explained as follows:		
	Calculated 22% tax on profit before tax (income)	-1,186	7,233
	Tax value of non-deductible value adjustments and		

Annual accounts 1 January – 31 December

cost	1,397	-6,714
Unrecognized Deferred Tax Asset	-211	-519
	0	0
	0,0 %	0,0 %

Effective tax rate As of December 31, 2021, the
 Company has an unrecognized tax asset of 25.1 mio.kr. (2020: 24.9 mio.kr.) relating to carry-over
 deficits. Recognition awaits the company to make taxable profits.

8 Long-term receivables

t.kr.	2021	2020
Balance at the beginning	57.500	71.344
Payments received	0	0
Accrued interest	1.151	0
Revaluation	4.849	-13.844
Balance at end	63,500	57,500

Long-term receivables include the company's receivable from Portinho S.A, the principal amount of EUR 9.55 million. At the beginning of 2021, an agreement was reached on payment deferral until 1 July 2023. If the plot of land is sold to the 3rd man before then, the entire amount is due for payment, unless otherwise agreed. Blue Vision A/S has a sub-pledge of 80% of the shares in Portinho S.A. Blue Vision A/S has the right to sell the claim in whole or in part to one or more 3rd month against the prior approval of the general meeting.

Management believes that there is a realistic possibility that Portinho S.A will have repaid the receivable by 1 July 2023. The company is continuously exploring the possibilities of selling the claim to 3rd part.

The receivable is included in the Company's balance sheet as of December 31, 2021 as a long-term receivable with an carrying value of 63.5 mio.kr. calculated as the principal amount of 71.3 mio.kr. less discount of 7.8 mio.kr. (2020: discounting 13.8 mio.kr.).

The value of the receivable is calculated on the basis of a calculated present value as at 31 December 2021 based on the receivable due on 1 July 2023 and discounting based on an estimate of credit and underlying project risk. The company points out that actual payments from the debtor or any sales value to one or more 3rd men may differ from the recognized present value in both positive and negative directions.

Annual accounts 1 January – 31 December

9 Equity

Equity t.kr.	2021	2020
14,542,437 pcs. A-shares	14.542	0
13,042,027 pcs. A-shares	0	13.042
4,112,400 pcs. B shares	4.112	0
70,050,243 pcs. B shares	0	70.050
	<u>18,655</u>	<u>83,092</u>

Cf. company announcement no. 3/2021, the capital reduction approved by the general meeting as of 31 December 2020 by provision for special reserve has been implemented in 2021, after the end of the 4-week proclamation period, which did not give rise to claims against the company. The appropriation was subsequently transferred to the free reserves.

As of October 29, 2021, the Company converted debt of t.kr 2,890. 2,745,610 Blue Vision shares of DKK 1.00, divided into 1,500,410 A shares and 1,245,200 B shares, respectively. The share capital then amounts to 18,654,837 shares of DKK 1.00 divided into 14,542,437 A-shares and 4,112,400 B shares.

Treasury shares

Following the Danish Business Authority's previous rejection of the capital reduction adopted by the Annual General Meeting in 2019, the company has technically held 67,183,043 treasury shares, which have been cancelled in connection with the completion and registration of the above-mentioned capital reduction on 2 March 2021.

In addition, the company holds 6,530 treasury A shares as of 31 December 2021 and 2020, and there has been no purchase or sale of treasury shares in 2021 and 2020.

Capital management

The Executive Board and the Board of Directors regularly assess the company's capital management.

As further discussed in the management report's section on "*Capital conditions*" and note 1, capital management is briefly focused on completing the acquisition of Reponex Pharmaceuticals A/S to ensure a sustainable basis for continuing to be a listed company, and where the acquisition is also expected to contain a number of elements that together contribute to strengthening the company's capital base.

Resultat per share	2021	2020
Average number of shares	27.792.803	83.092.270

Annual accounts 1 January – 31 December

Average number of treasury shares	6.868	67.189.573
Average number of shares outstanding	27,785,935	15,902,697
Profit for the year t.kr.	-5.391	-32.875
Profit per share, DKK	0,19	-1,94
Diluted profit per share, DKK	0,19	-1,94

10 Financial loans

t.kr.	2021	2020
Financial loans	7,000	0
Accrued interest	85	0
End-of-life balance	7.085	0
t.kr.	2021	2020
Long-term	6.582	0
Short-term	503	0
End-of-life balance	7.085	0
t.kr.	2021	2020
Loans contracted during the year	7.500	0
Installments in the year	-500	0
Accrued interest	85	0
End-of-life balance	7.085	0

Annual accounts 1 January – 31 December

Long-term financial loan relates to the settlement agreement for 7 mio.kr. (see note 11), where 0.5 mio.kr has been paid in 2021. 2021, so that outstanding debt amounts to 6.5 mio.kr. as of December 31, 2021. The loan bears interest at 5% p.a.

The loan is due no later than November 20, 2023, including accrued interest. The loan is due prior to 20 November 2023 if payment is received on the Portinho receivable before then, which, according to current agreements, is due and payable no later than 1 January 2023. July 2023. In this connection, Portinho has secured the receivable in the amount of up to 6.5 mio.kr.

Financial loans also include a separate short-term loan of 500 t.kr, due on 1 October 2022. No compensation has been granted for the loan.

11 Provisions

t.kr	. 2021	2020

Provision for guarantee obligations

Provisions have developed as follows:

t.kr.	2021	2020
Balance at the beginning	10.000	0
Provision for the year (2021: reversal)	-1.500	10.000
Transferred to financial loan	-7.000	0
	1.500	10.000
	1.500	10.000

End-of-life balance		10.000
1.500		10.000

In 2021, Blue Vision A/S entered into an agreement on the settlement of a guarantee obligation for 7 mio.kr, whereas in 2020, 8.5 mio.kr were set aside. The agreement resulted in the return

Annual accounts 1 January – 31 December

of 1.5 mio.kr. of the 2020 provision as income through the profit and loss account. See note 4.

Provisions of 1.5 mio.kr are then set aside. to cover a remaining potential guarantee obligation. According to the information available to Blue Vision A/S, the debtor fulfills the payment agreement for the underlying loan relationship, and is thus not currently asserted against Blue Vision A/S. The provision represents the assessed maximum risk on the guarantee obligation assumed by Blue Vision A/S in relation to the underlying loan relationship.

12 Bank debt

t.kr	. 2021	2020
	<u> </u>	<u> </u>
Operating credits	8.533	8.479
	<u>8.533</u>	<u>8.479</u>
Carrying value		

Bank debt mainly covers 2 operating credits with a total drawing right of 8,500 t.kr.

Bank debt is variable rate and has averaged 4.8% p.a. during the financial year.

For both operating credits, agreements have been entered into for monthly repayments in 2022 until 1 October 2022, when the outstanding debt becomes due and payable.

Portinho receivable for an amount up to 10 mio.kr. is collateralized for bank debt.

13 Debt to shareholders

t.kr	. 2021	2020
	<u> </u>	<u> </u>
Debt to shareholders	622	1.562
	<u>622</u>	<u>1.562</u>
Carrying value		

Annual accounts 1 January – 31 December

Debt to shareholders includes loans and outlays made by shareholders to cover the company's current payment obligations. The reduction in debt is primarily related to the fact that the share of the debt has been included in the debts that have been converted into share capital in 2021.

14 Subordinated convertible debt

t.kr	. 2021	2020
Loans 1	2,185	0
Loans 2	500	0
Carrying value		
2,685	0	0

Loan 1: The loan was granted on 31.12.2021 by the creditor (a company owned by the chairman of the board) taking over an existing debt obligation. The lender has the right to convert the loan into 50% a shares and 50% b shares to DKK 1 per share until 31.12.2022.

Loan 2: The loan was granted on 31.12.2021 by the creditor (a person close to the CEO/board member) assumption of an existing debt obligation. The lender is entitled to convert the loan into B shares at DKK 1 per share until 31.12.2022.

Both loans are granted as subordinated debt and bear interest at 2% p.a.

For both loans, lenders are also obliged to convert the loans if the company implements a decision on capital increase, including by contribution of other company, emission, etc. If the conversion right and conversion obligation are not actualized, both loans will be due on July 14, 2023.

15 Financial risks and financial instruments

Interest rate risks

The company's bank debt is variable rate, and the company is thus exposed to fluctuations in interest rates. *Credit risks*

As of December 31, 2021, the company has a receivable from the sale of Portinho S.A in 2018. The receivable is secured by a mortgage on shares in Portinho S.A (80% of the total capital of the company). Impairment has been recognised as of 31 December 2021, based on a risk-

Annual accounts 1 January – 31 December

weighted discounting in relation to the receivable becoming due no later than 1 July 2023. See also note 8.

Liquidity risks

As of December 31, debt obligations are due as follows (excluding any interest payments):

	Carrying value	Contract straight Cash flows	2021		
			Within 1 year	1 to 5 years	After 5 years
tkr.					
<i>Non-derivative financial instruments</i>					
Financial loans	7.085	7.085	503	6.582	0
Bank debt	8.533	8.533	8.533	0	0
Debt to shareholders	622	622	622	0	0
Convertible debt*	2.685	2.685	2.685	0	0
Supplier debt	654	654	654	0	0
December 31, 2021	19.579	19.579	12.997	6.582	0
2020					
	Carrying value	Contract straight Cash flows	Within 1 year	1 to 5 years	After 5 years
tkr.					
<i>Non-derivative financial instruments</i>					
Bank debt	8.479	8.479	8.479	0	0
Debt to shareholders	1.562	1.562	1.562	0	0
Supplier debt	3.260	3.260	3.260	0	0
December 31, 2020	13,301	13,301	0	0	0

*See note 1 and note 14, loan agreements on subordinated convertible debt contain conversion rights clauses and conversion obligations. If conversion rights and conversion obligations are not enforced in 2022, loans will not be due until 14 July 2023.

After the balance sheet date, the company entered into agreements with financial lenders for the provision of additional subordinated convertible loans for 0.9 mio.kr. a 3-mio.kr loan facility, respectively. from a 3-part. The subordinated convertible loan has been granted on the

Annual accounts 1 January – 31 December

same terms as the subordinated convertible loans included in the balance sheet as at 31 December 2021, so that there will be no maturity of liquid amounts in 2022. The 3 mio.kr loan facility, payable on an ongoing basis in 2022 and due on 1 October 2022.

Categories of financial instruments

tkr.	2021		2020	
	Accounting value	Day-value	Accounting value	Day-Value
Long-term receivables	63.500	63.500	57.500	57.500
Short-term receivables	145	145	82	82
Financial loans	7.085	7.085	0	0
Bank debt	8.533	8.533	8.479	8.479
Debt to shareholders	622	622	1.562	1.562
Supplier debt	655	655	3.260	3.260
Subordinated convertible debt	2.685	2.685	0	0
Financial liabilities measured at amortized cost price;	19.580	19.580	13.301	13.301
Loans and advances	63.645	63.645	57.582	57.582

16 Related Parties

Blue Vision A/S has no shareholders with controlling influence.

Blue Vision A/S has registered the following shareholders with 5% or more of the share capital:

- Jeanette Gyldstoft Borg
- Erhvervsinvest ApS

Annual accounts 1 January – 31 December

- NK Invest ApS
- Magnus Kjøller Holding ApS
- Peter Ole Jensen

As stated in note 2, the Executive Board and the Board of Directors have not received remuneration in 2020 and 2021. In 2021, costs have been incurred for a law firm in which a board member is a partner, with 104 t.kr. (2020: 935 t.kr.)

As of December 31, 2021, the company has debts to shareholders totalling 622 t.kr. (2020: 1,562 t.kr.). The shareholders in question have accepted payment deferral until 1 October 2022.

In October 2021, Blue Vision A/S converted 1,560 t.kr. of debt to equity holders to 1,421,951 shares.

As of 31.12.2021, subordinated loans have been granted from the shareholder (via the company owned by the Chairman of the Board) with 2,185 t.kr. by the related party having assumed overdue supplier debt, see also terms set out in note 14. After the balance sheet date, the same related party has granted additional subordinated convertible debt of 0.9 mio.kr. as set out in notes 1 and 15.

The company has a claim from Portinho S.A (see note 8) of 71,344 t.kr excluding interest. The company's ceo has special interests in Portinho S.A. and the shares owned by the director are pledged as collateral for the receivable. Blue Vision A/S' Chairman of the Board of Directors is about to be appointed to Portinho S.A's Board of Directors.

17 Contingent assets, liabilities and collateral

Contingent assets

In 2021, Blue Vision A/S has concretized claims for damages against the sellers of Heartcare ApS as well as separately Blue Vision A/S' former chairman nicolai Dines Kærgaard and former ceo Peter Hauge Jensen. The provisional claim for damages amounts to 15.0 mio.kr. Likewise, it is claimed that the sellers of Heartcare ApS return the purchase price of a total of nominally 4 mio.kr. Shares. The requirements are not included in the company's balance sheet. Blue Vision A/S is currently exploring the possibility of divesting the claims to another independent legal entity that is not affiliated or affiliated to Blue Vision A/S, in exchange for the buyer's payment of the costs of conducting the cases and with a scheme where net proceeds are shared between Blue Vision A/S and the buyer. The company has an unrecognized tax asset. See note 7.

Contingent liabilities

The bankruptcy estate of Contra A/S in bankruptcy has made a claim for annulment of 450 t.kr. Applicable. The claim is disputed and no provisions are included in the annual accounts.

Annual accounts 1 January – 31 December

Guarantees

Portinho receivable with an carrying value of 63,5 mio.kr. as of 31 December 2021 (see note 8), collateral has been provided for primary bank debt up to 10 mio.kr. and secondarily to collateralize financial loans of an amount of up to K6.5million.

18 Post-balance sheet events

After the balance sheet date, the Company has entered into agreements with lending banks to extend the maturity date for operating credits for a total of 8.5 mio.kr., after which the debt will be settled with monthly repayments until October 1, 2022, when the remaining debt thereafter becomes due for full and final repayment.

After the balance sheet date, the company entered into agreements with financial lenders for the provision of additional subordinated convertible loans for 0.9 mio.kr. respectively, a 3-mio.kr borrowing facility from a 3.part. The subordinated convertible loan has been granted on the same terms as the subordinated convertible loans included in the balance sheet as at 31 December 2021, so that there will be no maturity of liquid amounts in 2022. The loanfacility of 3 mio.kr will be paid out on an ongoing basis in 2022 and due on 1 October 2022.

In March 2022, the Company's CEO Jeanette G. Borg resigned from the position of resignation on 29 April 2022.

19 Accounting policies

The company's annual accounts are presented in accordance with international financial reporting standards as approved by the EU and Danish disclosure requirements for annual reports for listed companies.

Basis for preparation

Blue Vision A/S has implemented the new and amended accounting standards (IFRS) and interpretations (IFRIC), which are mandatory for financial reporting for 2021. The implementation of the new and amended standards and interpretations has not led to any changes in the recognition and measurement of the financial statements.

The annual report is presented in Danish kroner rounded to the nearest DKK 1,000.

Implementation of new and changed standards and interpretations

Implementation of new and amended standards and interpretations with entry into force 1. January 2021 has not given rise to any changes in accounting policies.

Annual accounts 1 January – 31 December

Standards and interpretations not yet in force

At the time of publication of this annual report, there are a number of new or amended standards and interpretations which have not yet entered into force and have therefore not been incorporated into the Company's annual accounts. It is management's assessment that these will not have a significant impact on the financial statements for the coming financial years.

Conversion of foreign currency

Transactions in foreign currencies were converted during the year at the rate of the transaction day. Exchange rate differences that occur between the rate of the transaction date and the rate on the payment date are recognized in the income statement under financial income or expenses.

Investment assets, receivables, debts and other monetary items denominated in foreign currencies shall be converted at the exchange rate of the balance sheet date.

The difference between the rate on the balance sheet date and the rate at the time of the receivable or debt arising or the rate shown in the late annual report shall be recognised in the profit and loss account under financial income and expenses.

Income statement

Administrative costs

Administrative expenses include miscellaneous company expenses and other costs arising from the company's operations.

Financial income and expenses

Financial income and expenses contain interest and exchange rate adjustments, which are not considered to be an integral part of the value adjustment of the company's investment assets. In addition, the amortization of liabilities, allowances and allowances is included under the advance tax scheme.

Tax on profit for the year

Tax due and receivable is shown under current assets/liabilities. Joint taxation contributions due or receivable are recognised in the balance under claims on or payables to affiliated undertakings.

Balance

Annual accounts 1 January – 31 December

Receivables

Receivables are measured at amortized cost. Write-downs are made to counter losses where an objective indication has occurred that an individual receivable or portfolio of receivables has deteriorated.

Write-downs are calculated as the difference between the carrying value and the present value of the expected cash flows, including the realisation value of any collateral received. The discount rate shall be the effective interest rate applied at the time of first recognition on each receivable or portfolio.

The recognition of interest on written receivables is calculated on the written-down value at the effective interest rate for each receivable.

Equity

Dividends

Dividends are recognized as a liability at the time of adoption at the annual general meeting (the date of declaration). Dividends proposed for the year are shown as a separate item under equity.

Extraordinary dividends are recognised as a liability at the time of the decision.

Purchase and sale of treasury shares

The purchase and sale of treasury shares is carried directly into the equity in "Transferred profit". Dividends for treasury shares are recognized directly in transferred comprehensive income in equity.

Payable tax and deferred tax

Current tax liabilities and outstanding current tax are recognised in the balance sheet as calculated tax on the taxable income of the year, adjusted for tax on previous years' taxable income and for taxes paid on account.

Deferred tax is measured by the balance sheet-oriented debt method by all temporary differences between the carrying and tax value of assets and liabilities.

Deferred tax assets, including the tax value of carry-forward tax losses, are recognized under other non-current assets at the value to which they are expected to be used, either by offsetting against tax on future earnings or by offsetting deferred tax liabilities within the same legal tax entity and jurisdiction. Deferred tax assets are assessed annually and recognized only to the extent that they are likely to be utilized.

Deferred tax is measured on the basis of the tax rules and tax rates that will apply under the balance sheet date legislation when the deferred tax is expected to be triggered as current tax. Changes in deferred tax due to changes in tax rates are recognised in the comprehensive income for the year.

Annual accounts 1 January – 31 December

Provisions for commitments

These commitments include legal and actual liabilities which are uncertain in terms of amount or due date and which relate to the financial year or previous financial years. Provisions are measured at the best estimate of the amounts needed to settle the obligation on the balance sheet date.

Financial commitments

All financial liabilities are measured at amortized cost.

Cash flow statement

The cash flow statement shows cash flows by operating, investment and financing activity for the year, the year's shift in cash and cash equivalents at the beginning and end of the year.

Cash flows from operating activities are calculated according to the indirect method as profit before tax adjusted for non-cash operating items, change in operating capital, interest received and paid, dividends received and corporate tax paid.

Cash flows from investment activity include payments related to the purchase and sale of portfolio companies and other investment activities.

Cash flows from financing activities include changes in the size or composition of share capital and associated costs, as well as borrowing, repayment of interest-bearing debt, purchase and sale of treasury shares and payment of dividends to shareholders.

Cash and cash equivalents include cash and cash equivalents.

Ratios

The key figures given in the annual report are calculated as follows:

Solvency ratio	$\frac{\text{Equity, end} \times 100}{\text{Total Passver, end}}$ of
	Result
Earnings per share (EPS Basic)	$\frac{\text{Result}}{\text{Average number of shares outstanding}}$
	Diluted result
Diluted earnings per share (EPS-D)	$\frac{\text{Diluted result}}{\text{Diluted average number of shares outstanding}}$
	$\frac{\text{Equity}}{\text{Number of shares at end}}$
Net asset value per share	
	$\frac{\text{Stock exchange rate}}{\text{Intrinsic value}}$
Exchange rate/net asset value (P/BV)	